Corbus Pharmaceuticals Holdings (STU:3371) Buyback Yield %: 0.00 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
38 GF Score
Price €7.89
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Buyback Yield %?

Corbus Pharmaceuticals Holdings STU:3371 +2.67% 38 Buyback Yield % is 0.00 as of Jul. 18, 2026. GuruFocus rates STU:3371 with a GF Score™ of 38/100 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 740 Biotechnology companies, Corbus Pharmaceuticals Holdings ranks worse than 135135% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Corbus Pharmaceuticals Holdings's current buyback yield was 0.00%.

Corbus Pharmaceuticals Holdings Buyback Yield % Related Terms

Corbus Pharmaceuticals Holdings Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Buyback Yield % Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -84.48 0.00 -0.37 -118.97 -54.81

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -112.63 -42.49 0.01 -54.01 0.00

STU:3371 vs PRQR, NRXP, CRBU: Buyback Yield % Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Buyback Yield % falls into.


STU:3371
38GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Corbus Pharmaceuticals Holdings's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 66.122) / 120.6422
=-54.81%

Corbus Pharmaceuticals Holdings's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 140.1381
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Corbus Pharmaceuticals Holdings (STU:3371) has a Buyback Yield % of 0.00 as of Jul. 18, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Corbus Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 740 companies in the Biotechnology industry.
Is Corbus Pharmaceuticals Holdings' Buyback Yield % too high?
Corbus Pharmaceuticals Holdings' current Buyback Yield % is 0.00. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Buyback Yield % compare to PRQR and NRXP?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 740 companies for Buyback Yield %. This places Corbus Pharmaceuticals Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (STU:3371) is currently considered Significantly Overvalued. The current Buyback Yield % is 0.00. Corbus Pharmaceuticals Holdings' overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current Buyback Yield % is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
38GF Score

Get the complete analysis for STU:3371

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.89
Price